Phase 1 lead‐in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed …
S Maraka, MD Groves, AG Mammoser… - Cancer, 2019 - Wiley Online Library
Background Repurposed memantine, mefloquine, and metformin have putative anticancer
activity. The objective of this phase 1 study was to determine the maximum tolerated doses …
activity. The objective of this phase 1 study was to determine the maximum tolerated doses …
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed …
S Maraka, MD Groves, AG Mammoser… - …, 2019 - mdanderson.elsevierpure.com
Background: Repurposed memantine, mefloquine, and metformin have putative anticancer
activity. The objective of this phase 1 study was to determine the maximum tolerated doses …
activity. The objective of this phase 1 study was to determine the maximum tolerated doses …
Phase 1 lead‐in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed …
S Maraka, MD Groves, AG Mammoser… - Cancer, 2018 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Background</jats: title>< jats: p> Repurposed memantine,
mefloquine, and metformin have putative anticancer activity. The objective of this phase 1 …
mefloquine, and metformin have putative anticancer activity. The objective of this phase 1 …
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed …
S Maraka, MD Groves, AG Mammoser… - Cancer, 2018 - europepmc.org
Background Repurposed memantine, mefloquine, and metformin have putative anticancer
activity. The objective of this phase 1 study was to determine the maximum tolerated doses …
activity. The objective of this phase 1 study was to determine the maximum tolerated doses …
[HTML][HTML] Phase 1 Lead-in to a Phase 2 Factorial Study of Temozolomide Plus Memantine, Mefloquine, and Metformin as Postradiation Adjuvant Therapy for Newly …
S Maraka, MD Groves, AG Mammoser… - Cancer, 2019 - ncbi.nlm.nih.gov
BACKGROUND: Repurposed memantine, mefloquine, and metformin have putative
anticancer activity. The objective of this phase 1 study was to determine the maximum …
anticancer activity. The objective of this phase 1 study was to determine the maximum …
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed …
S Maraka, EP Sulman, KR Hess, KD Aldape… - Cancer, 2019 - hero.epa.gov
Background Repurposed memantine, mefloquine, and metformin have putative anticancer
activity. The objective of this phase 1 study was to determine the maximum tolerated doses …
activity. The objective of this phase 1 study was to determine the maximum tolerated doses …
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed …
S Maraka, MD Groves, AG Mammoser… - …, 2019 - ohiostate.elsevierpure.com
Background: Repurposed memantine, mefloquine, and metformin have putative anticancer
activity. The objective of this phase 1 study was to determine the maximum tolerated doses …
activity. The objective of this phase 1 study was to determine the maximum tolerated doses …
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed …
S Maraka, MD Groves, AG Mammoser… - Cancer, 2019 - pubmed.ncbi.nlm.nih.gov
Background Repurposed memantine, mefloquine, and metformin have putative anticancer
activity. The objective of this phase 1 study was to determine the maximum tolerated doses …
activity. The objective of this phase 1 study was to determine the maximum tolerated doses …